FDA Approves Selumetinib for Select Pediatric Patients 1 Year of Age and Older

On September 10, the FDA approved selumetinib granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

For more information, read the FDA announcement and visit the Koselugo website.

Posted on 9/11/2025